Leveraging Real-World Evidence (RWE) in Rare Disease Drug Development

The path to regulatory approval and market access for rare disease therapies presents unique challenges. With small patient populations and heterogeneous data, the development of therapeutics for rare diseases requires innovative approaches. That’s where Real-World Evidence (RWE) comes into play.

In this expert video, Ananth Kadambi, PhD, Vice President, Real World Evidence and Modeling Solutions, shares key insights on how RWE is transforming the development of rare disease therapies and accelerating their regulatory approval and market access. RWE is revolutionizing rare disease research, making drug approvals faster, more cost-effective, and ensuring better patient outcomes.